课题基金 / 基金详情

Thansfection of oncogenes into dendritic cells utilizing receptor-mediated endocytosis of liposomes

Thansfection of oncogenes into dendritic cells utilizing receptor-mediated endocytosis of liposomes
利用受体介导的脂质体内吞作用将癌基因转染到树突状细胞中
批准号:
15591004
负责人:
KADOWAKI Norimitsu
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

KADOWAKI Norimitsu的其他基金

相似基金

相关文献

中文摘要
翻译
脂质体是一种很有前途的载体,可将外源性抗原递送至树突状细胞(DC)用于肿瘤免疫治疗。已经显示将外源性抗原靶向DC上的Fcγ受体导致抗原衍生肽在MHC I类以及II类分子上的有效呈递。在这里,我们研究了内吞物理化学优化的含有抗原的脂质体与IgG缀合的DC是否有效地在MHC I类和II类分子上呈递抗原,从而诱导强烈的抗肿瘤免疫应答。直径为200 nm的IgG偶联脂质体(未连接聚乙二醇)最有效地被DC内吞。通过CD 32内吞含破伤风类毒素(TT)IgG脂质体的人单核细胞来源的DC比含TT裸脂质体或可溶性TT的DC刺激的CD 4 ^+ T细胞更强。用内吞含有卵清蛋白(OVA)的IgG-脂质体,但不含OVA的裸脂质体或可溶性OVA的DC免疫小鼠,完全阻止了表达OVA的淋巴瘤细胞的生长。重要的是,给予具有已建立的表达OVA的肿瘤的小鼠内吞含有OVA的IgG脂质体的DC强烈抑制肿瘤生长。本研究证明了IgG-脂质体具有适合于将抗原递送至DC的理化性质,并为IgG-脂质体用于使用DC的肿瘤免疫治疗铺平了道路。
英文摘要
Liposomes represent a promising vehicle to deliver exogenous antigens to dendritic cells (DCs) for tumor immunotherapy. Targeting exogenous antigens to Fcγ receptors on DCs has been shown to result in efficient presentation of antigen-derived peptides on MHC class I as well as class II molecules. Here we investigated whether DCs that endocytosed physicochemically optimized, antigen-containing liposomes conjugated with IgG efficiently present antigens on MHC class I and class II molecules, and consequently induce strong anti-tumor immune responses. IgG-conjugated liposomes with 200 nm in diameter without attaching polyethylene glycol were most efficiently endocytosed by DCs. Human monocyte-derived DCs that endocytosed tetanus toxoid (TT)-containing IgG-liposomes via CD32 stimulated CD4^+ T cells more strongly than DCs pulsed with TT-containing bare liposomes or with soluble TT. Immunization of mice with DCs that endocytosed ovalbumin (OVA)-containing IgG-liposomes, but not OVA-containing bare liposomes or soluble OVA, completely prevented the growth of OVA-expressing lymphoma cells. Importantly, administration of DCs that endocytosed OVA-containing IgG-liposomes to the mice with established OVA-expressing tumors strongly suppressed tumor growth. This study demonstrates an IgG-liposome with physicochemical properties suitable for delivering antigens to DCs, and paves the way to the application of IgG-liposomes for tumor immunotherapy using DCs.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1097/01.cji.0000190169.61416.f5
发表时间: 2006-03
期刊: Journal of Immunotherapy
影响因子: 3.9
作者: [K. Kawamura;N. Kadowaki;R. Suzuki;S. Udagawa;S. Kasaoka;N. Utoguchi;T. Kitawaki;N. Sugimoto;N. Okada;K. Maruyama;T. Uchiyama]
通讯作者: K. Kawamura;N. Kadowaki;R. Suzuki;S. Udagawa;S. Kasaoka;N. Utoguchi;T. Kitawaki;N. Sugimoto;N. Okada;K. Maruyama;T. Uchiyama
DOI: 10.1189/jlb.1204733
发表时间: 2005-05-01
期刊: JOURNAL OF LEUKOCYTE BIOLOGY
影响因子: 5.5
作者: [Tabata, S, Kadowaki, N, Uchiyama, T]
通讯作者: Uchiyama, T
DOI: 10.1016/j.exphem.2004.11.013
发表时间: 2005-03-01
期刊: EXPERIMENTAL HEMATOLOGY
影响因子: 2.6
作者: [Kaneko, H, Hori, T, Uchiyama, T]
通讯作者: Uchiyama, T
Immune regulation by controlling vesicular functions in dendritic cells
  • 批准号:
    22590434
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.91万
  • 财政年份:
    2010
  • 负责人:
    KADOWAKI Norimitsu
  • 依托单位:
Analysis of myeloid suppressor cells in tumor-bearing mice and humans and in patients after chemotherapy
  • 批准号:
    17590994
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $1.92万
  • 财政年份:
    2005
  • 负责人:
    KADOWAKI Norimitsu
  • 依托单位:
Development of effective hematopoietic stem cell transplantation/cellular immunotherapy for adult T-cell leukemia
  • 批准号:
    17016034
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas
  • 资助金额:
    $35.84万
  • 财政年份:
    2005
  • 负责人:
    KADOWAKI Norimitsu
  • 依托单位:
Recovery of Natural Interferon-α/β-producing Cells after Allogeneic Hematopoietic Stem Cell Transplantation
  • 批准号:
    13671062
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.3万
  • 财政年份:
    2001
  • 负责人:
    KADOWAKI Norimitsu
  • 依托单位:
国内基金
海外基金
蛋白精氨酸甲基化转移酶PRMT5调控PPARG促进巨噬细胞M2极化及其在肿瘤中作用的机制研究
  • 批准号:
    82371738
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    郑英霞
  • 依托单位:
原发性胆汁性肝硬化(PBC)免疫生物治疗的细胞与分子机制
  • 批准号:
    81130058
  • 项目类别:
    重点项目
  • 资助金额:
    260.0万元
  • 批准年份:
    2011
  • 负责人:
    廉哲雄
  • 依托单位:
用识别EBV相关淋巴瘤抗原多肽的T细胞受体做转基因免疫治疗
  • 批准号:
    81041002
  • 项目类别:
    专项基金项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2010
  • 负责人:
    岑溪南
  • 依托单位: